Crossmark

Anti-IL 17 biologics and pyoderma gangrenosum – therapeutic or causal?

Crossref DOI link: https://doi.org/10.1007/s00403-024-03689-4

Published Online: 2025-01-13

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wanzenberg, Anna

Keshock, Elise

Sami, Naveed https://orcid.org/0000-0003-4141-9468
License Information

Text and Data Mining valid from 2025-01-13

Version of Record valid from 2025-01-13
More Information

Article History

Received: 29 October 2024

Revised: 17 December 2024

Accepted: 20 December 2024

First Online: 13 January 2025

Declarations

:

: The authors declare no competing interests.